Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Baxter Healthcare Corporation

Approvalsdevice change approved (PMA)7 Nov 2026

Baxter Healthcare Corporation

7 Nov 2026: Device change approved (PMA) · PerClot Absorbable Hemostatic Powder Accessory Tips. Recorded in the openFDA device PMA data.

View the source record

Decided
7 Nov 2026
Device
PerClot Absorbable Hemostatic Powder Accessory Tips
Specialty
General, Plastic Surgery
Type
Supplement (Normal 180 Day Track No User Fee)
Reason
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Reference
P210036 S010
Location
Round Lake, IL
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Baxter Healthcare Corporation

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Baxter Healthcare Corporation in our registers.

More in General, Plastic Surgery

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.